Can a Ring Detect Menopause? A Critical Appraisal of the Oura Ring’s Perimenopause and Menopause Claims

Abstract

Background. Menopause is a retrospective clinical diagnosis, made after twelve consecutive months of amenorrhoea. The menopausal transition preceding it is staged by menstrual-cycle criteria and accompanied, in most women, by vasomotor symptoms. Oura Health Oy has progressively positioned its finger-worn ring as a tool for the perimenopause. It published an aggregate “Perimenopause Report” in 2024, launched a Perimenopause Check-In in 2025 and Menopause Insights in 2026, and holds a pending patent for “menopause and hot flash detection.”

Objective. To set out what diagnosing and staging the menopausal transition requires, to determine what a finger-worn temperature and photoplethysmography sensor can physiologically observe, and to appraise Oura’s published claims and evidence against that standard.

Findings. Oura does not explicitly claim to diagnose menopause, and its disclaimers state that the ring is not a medical device. Its materials nevertheless present biometric correlates as “an objective, domain-level picture” of symptom burden and state that ring data can “flag meaningful deviations” across the perimenopausal transition. No peer-reviewed study has validated any Oura metric against STRAW+10 staging, against hormonal criteria, or against sternal skin conductance, the reference measure for hot flashes. The 2024 report used age bands as a proxy for reproductive stage, relied on self-selected users’ symptom tags, had no age-matched premenopausal control, and was not peer-reviewed. Its reported 20–30% decline in heart-rate variability is therefore confounded by chronological ageing. The ovulation-detection validation on which Oura’s cycle features rest was restricted to ovulatory cycles, which excludes the anovulatory cycles characteristic of the late transition. That study reported a mean absolute error of 1.26 days, whereas Oura’s Chief Executive stated in a filing with the US Securities and Exchange Commission that predictions are accurate to “plus or minus half a day.” The same filing describes nocturnal measurement as free of “noise” and invokes the fall in core temperature during sleep, whereas the ring records finger skin temperature, which rises at sleep onset. The filed interview makes no claim that the ring detects menopause. The company’s Menopause Impact Scale is described as “clinically validated,” but we identified no published psychometric validation. Nocturnal finger-temperature rises are intrinsically confounded by the physiological distal vasodilatation of sleep onset, by ambient conditions, and by the wide differential diagnosis of night sweats.

Conclusions. A ring cannot detect menopause, and there is no evidence that it can stage the transition or detect vasomotor events with known accuracy. At most, it records non-specific nocturnal physiology whose association with the transition has not been validated. Symptom questionnaires combined with menstrual history remain the basis of diagnosis in women over 45. Biochemical testing is reserved for younger women and for suspected premature ovarian insufficiency. Clinicians should not accept ring-derived patterns as evidence for or against the menopausal transition, and should investigate night sweats on their merits.

Keywords: menopause; perimenopause; menopausal transition; STRAW+10; vasomotor symptoms; hot flashes; wearable devices; finger temperature; Oura Ring; device validation

Article details

Article type: Review / critical appraisal
Corresponding author: Darshana Goakar, Peak Health Center, San Francisco, California, United States.
License: Creative Commons Attribution 4.0 International (CC BY 4.0)

Declarations

Author contributions

Bomi Joseph: Conceptualization, article conception and design, development of the manuscript outline, and writing of the manuscript.

Darshana Goakar: Research and investigation, source identification, collection of supporting documents, and compilation of the reference literature.

Both authors reviewed and approved the final manuscript.

Funding

This work was supported by Peak Health Center, San Francisco, California, USA (ROR: https://ror.org/04b23x642).

Competing interests

Bomi Joseph is the inventor of the Deep Health® Device, a health-measurement technology. Darshana Goakar declares no competing interests.

Data availability

No new data were generated or analyzed specifically for this article. All data, figures, performance measures, and other quantitative information discussed in the manuscript derive from the publicly available sources cited in the article.

Use of artificial-intelligence tools

No artificial-intelligence tools were used in the research, analysis, preparation, or writing of this manuscript.

Note on sources

Descriptions of Oura products and features, and performance figures attributed to Oura, are derived from company publications, press releases, and other publicly available Oura materials current as of September 2026. Unless otherwise stated in the manuscript, these company- reported claims and figures have not been independently verified by the authors.